The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.
The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.
TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION
申请人:Napoletano Mauro
公开号:US20130079339A1
公开(公告)日:2013-03-28
The invention discloses compounds of formula I
wherein Y is a group of formula A, B, C, D, or E:
and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description.
The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.
TRPV1 vanilloid receptor antagonists with a bicyclic portion
申请人:Napoletano Mauro
公开号:US09216975B2
公开(公告)日:2015-12-22
The invention discloses compounds of formula I
wherein Y is a group of formula A, B, C, D, or E:
and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description.
The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.